Register
  • Community
    • Physicians
    • Editors
    • Experts
    • Code of conduct
    • Blog
  • Company
    • About
    • Publications
    • Press
    • Careers
  • Programs
    • Journal Club
    • Targeted Topic
    • Clinical Trial
    • Tumor Board
  • Contact Us
  • Sign in

Neurology

Breast Cancer   

Questions discussed in this category


How do you manage neuropathic chemotherapy agents in patients with underlying multiple sclerosis?
Are there contraindications to drugs like oxaliplatin or abraxane? Does chronicity or severity of the patient's underlying symptoms play a role in yo...
1 Answer available

How do you modify TNBC neoadjuvant chemotherapy in patients with multiple sclerosis?
1 Answer available

How would you manage adjuvant endocrine therapy for a postmenopausal patient with early stage HR+ breast CA who develops an ischemic CVA on an AI?
Presuming that work-up for cardioembolic sources is negative, how would you proceed?
1 Answer available
12137101449444


Papers discussed in this category


Circulation, 2020 Feb 17
Aromatase Inhibitors and the Risk of Cardiovascular Outcomes in Women With Breast Cancer: A Population-Based Cohort Study.

N. Engl. J. Med.,
Pembrolizumab for Early Triple-Negative Breast Cancer.

Related Topics in Neurology

  • Breast Cancer
  • Hematologic Malignancies
  • Radiation Oncology
  • Gynecologic Cancers
  • Palliation
  • Neuro-Oncology
  • Gastrointestinal Cancers
  • Non-malignant Disease
  • Pediatric Oncology
  • Thoracic Malignancies

Copyright © 2022 theMednet
All Rights Reserved.